The RAF-1 serine-threonine kinase plays a central role in signal transduction pathways involved in cell survival and proliferation. The concept of RAF-1-targeted disruption of cell signaling for therapeutic purposes was first advanced in 1989 with the demonstration of tumor growth inhibition in athymic mice and radiosensitization of human squamous carcinoma cells transfected with a vector expressing antisense cDNA. However, the clinical application of antisense strategies has awaited the development of improved antisense oligonucleotide technologies and drug delivery methods. Nuclease-resistant phosphorothioated antisense oligonucleotides have been the focus of pharmaceutical industry attention. In vivo delivery of nuclease-sensitive, natural backbone/phosphodiester oligonucleotides has remained a formidable challenge. Liposomal encapsulation of antisense oligonucleotides protects them from degradation and enhances drug delivery. Here, we review the importance of targeting RAF-1 signaling in cancer therapy and the preclinical and clinical experiences with a liposomal formulation of a nuclease-sensitive, ends-modified antisense RAF oligonucleotide.
Radiation therapy is used for the curative treatment of cancers. However, radiation responses of tumors vary with histology, doubling time, oxygenation, availability of nutrients, repair capacity and other factors (Peters et al., 1982) . Some tumors are cured by conventional doses of radiation therapy while others are not. Furthermore, radiation responses of tumors with similar histologies may exhibit considerable heterogeneity, which may result in treatment cure or failure. Radiation resistance has been attributed, in part, to genetic factors that may lead to a less radiation-responsive phenotype (Weichselbaum et al., 1988) .
To improve local-regional tumor control, radiation therapy may be used with chemotherapy in combined modality treatment protocols. Several clinically important drugs (for example, 5-FU and cis-platinum) have been shown to sensitize cancer cells to radiation therapy, resulting in improved cure rates in gynecologic and gastrointestinal cancers (Krook et al., 1991; Morris et al., 1999) . Radiation sensitization of cancers offers the ability to enhance local tumor control and disease-free survival. The need for additional radiation sensitization drugs has been identified as an important goal for improving the therapeutic ratio in cancer treatment (Poggi et al., 2001) .
Recent research has focused on molecular targets for radiation sensitization of cancer cells. It is of particular interest that several potential target proteins for radiation sensitization, which have been identified in growthrelated cellular signaling pathways, either converge on RAF (for example, epidermal growth factor receptor (EGFR) and RAS) or crosstalk through RAF (for example, NF-kB). Thus, RAF provides a target that is pivotal to signaling pathways that lead to the induction of gene expression. The expression of early and late response genes may be critical for cellular survival .
RAF-1 as a validated target in cancer therapy
RAF-1 is an B75 kDa cytosolic protein serine-threonine kinase (Moelling et al., 1984) . It plays an important role in cell growth, proliferation and cell survival. It is a central signal transducer for several receptor and nonreceptor tyrosine kinases, and for nontyrosine kinases (Morrison et al., 1988; App et al., 1991; Turner et al., 1991; Kyriakis et al., 1992; Marshall, 1996) . Depending on the cell type and stimulus, RAF-1 interacts with a large number of different types of proteins. These include scaffolds/adaptors (kinase suppressor of RAS (KSR) and BAG-1), cofactors (14-3-3), chaperones (heat-shock proteins, HSP90, and HSP70), substrates (MAPK/ERK kinase (MEK)), Rb, the myosin-binding subunit of myosin phosphatase (MBS), inhibitors (RAF kinase inhibitor protein (RKIP)), or activators of RAF-1 (RAS, protein kinase C (PKC) and other kinases) (Kasid and Suy, 1998; Kolch, 2000; Dhillon and Kolch, 2002) . Transfection with c-RAF-1 sequences produces morphologic and biochemical evidence of transformation (Kolch et al., 1991) . The importance of RAF-1 activity has been implicated in solid tumors and hematological malignancies, and in metastasis (Kasid et al., 1987; Ward et al., 2001; Podar et al., 2001; Khatib et al., 2002) . Activation of the RAS-RAF-ERK pathway or overexpression of oncogenic RAS or RAF has been associated with enhanced expression of vascular endothelial growth factor (VEGF), and this may be secondarily linked to the angiogenic effects of VEGF in endothelial cells (Grugel et al., 1995; D'Angelo et al., 1997; Eliceiri et al., 1998; Takahashi et al., 1999; Veikkola et al., 2000; Podar et al., 2001; Shu et al., 2002) . Mutant RAF, defective in binding to ATP, blocks angiogenesis in response to basic fibroblast growth factor (bFGF) or VEGF (Hood et al., 2002) . Angiogenesis is also dependent on interaction between components of the extracellular matrix (ECM) and integrins, a family of heterodimeric transmembrane proteins (Friedlander et al., 1995; Aplin et al., 1998) . Activated integrin avb3 is expressed on vascular cells and invasive tumor cells, and integrin-mediated signal transduction involves RAF and extracellular signal-regulated kinase (ERK) (Felding-Habermann et al., 1992; Chen et al., 1996; Schlaepfer et al., 1998; Eliceiri and Cheresh, 1999) . RAF-1 plays a role in cell cycle regulation via its interaction with the retinoblastoma protein (Wang et al., 1998) , and in cytoskeletal reorganization via its association with vimentin, vimentin kinases and myosin phosphatase (Janosch et al., 2000; Broustas et al., 2002) . Several reports indicate that the intensity and duration of the signal may contribute to a differential role for RAF-1 in the cell cycle (Kerkhoff and Rapp, 1998) . RAF-1 regulates transcription factors and is consequently associated with transcription/translation modulation of several genes (Bruder et al., 1992; Shengfeng and Sedivy, 1993; Finco and Baldwin, 1993; Bertrand et al., 1995; Patel et al., 1997; Xu et al., 1998; Frost et al., 2000; Ries et al., 2000; Schulze et al., 2001) . Accordingly, the RAF kinase inhibitor protein RKIP has been shown to negatively regulate ERK and NF-kB signaling downstream of RAF-1 (Yeung et al., 2000 (Yeung et al., , 2001 .
Mechanisms of RAF-1-mediated cell survival are not fully defined. Exposure of cells to ionizing radiation (IR) stimulates the membrane recruitment, tyrosine phosphorylation and activation of RAF-1 protein kinase in head and neck squamous carcinoma and breast carcinoma cells (Kasid et al., 1996; Suy et al., 1997) . Irradiation also enhances interactions between Grb2 and SOS, and RAS and RAF proteins, and activation of ERK, and transcription factors AP-1, NFkB, Oct-1 and Sp-1 (Suy et al., 1997; Dent et al., 1999; MeighanMantha et al., 1999) . Dominant negative regulatory mutations that inhibit RAF kinase activity also abrogate the physiological and biochemical responses of cells to serum, growth factors, tumor promoter (PMA), oncogenic p21 and UV radiation (Kolch et al., 1991; Devary et al., 1992) . Conversely, constitutively activated RAF-1 substitutes for the growth factor requirements of normal or immortalized cells and enhances resistance of tumor cells to the toxic effects of IR and anticancer drugs (Kasid et al., 1989; Pirollo et al., 1989; Troppmair et al., 1992; Skorski et al., 1995; Rasouli-Nia et al., 1998; Salomoni et al., 1998; von Gise et al., 2001) . Expression of exogenous RAF-1 is sufficient to confer radioresistance, whereas cotransfection of RAF-1 and Myc is required for neoplastic transformation in immortalized human bronchial epithelial cells (BEAS-2B), suggesting that the mechanisms of RAF-1-mediated radioresistance and transformation are distinct (Pfeifer et al., 1998) .
In several tumor cell lines, selective downregulation of RAF-1 expression results in activation of caspase-3, PARP cleavage and apoptosis (Lau et al., 1998) . RAF-1 activity has also been linked with the antiapoptotic function of BCL-2 via phosphorylation of Bad, inhibition of IR-induced apoptosis, and restoration of cell cycle arrest through the p53 pathway (Canman et al., 1995; Wang et al., 1996; Kasid and Suy, 1998; Zhong et al., 2001) . Reports using genetic knock-outs of the mouse c-RAF-1 gene demonstrate a MEK-independent role for RAF-1 in cell survival and differentiation (Chen et al., 2001; Mikula et al., 2001) . Such mice die of apoptosis and vascular defects (Huser et al., 2001) .
In hematopoietic cells, RAF-1 and a constitutively active mutant of Akt (protein kinase B), a downstream effector of phosphatidylinositol 3-kinase (PI3K), show a synergistic effect on cell survival (von Gise et al., 2001 ). This appears to be in agreement with the involvement of PI3K in RAF-1-mediated ERK activation via p21-activated serine-threonine kinase (PAK) (King et al., 1997; Pandey et al., 1999; Wennstrom and Downward, 1999; Chaudhary et al., 2000; Kolch, 2000; Sun et al., 2000; Ballif and Blenis, 2001 ). RAF-1 also activates the transcription factor NF-kB in a PAK1-dependent manner . PI3K may also contribute negative signals to ERK. For example, phosphorylation of RAF-1 on serine 259 is an important mechanism of repression of RAF-1 activity (Dhillon et al., 2002a, b; Dumaz et al., 2002) . Depending on the cell type, activated Akt may generate a survival signal via BCL-2 by phosphorylating and inactivating Bad (del Peso et al., 1997; Wu et al., 1998; Sun et al., 1999) , but may also phosphorylate RAF-1 on serine 259, undermining the control of cell survival by RAF-1 (Rommel et al., 1999; Zimmermann and Moelling, 1999) . Interestingly, both Akt and RAF-1 may play roles in the antiapoptotic function of the phosphatase Cdc25A (Fuhrmann et al., 2001) .
A somewhat similar scenario can be visualized in regard to another therapeutic target protein kinase A (PKA), a cAMP-dependent protein kinase . PKA provides a survival signal by phosphorylating Bad (Lizcano et al., 2000; Virdee et al., 2000) . PKA also inhibits RAF-1 via serine 259 phosphorylation, blocking ERK activation and ERKinduced gene expression, and enhancing apoptosis (Weissinger et al., 1997; Dhillon et al., 2002a, b) . It is noteworthy, however, that PI3K may act upstream or downstream of RAS (Bar-Sagi and Hall, 2000; Ballif and Blenis, 2001) , and RAS-mediated radioresistant response may be a result of RAF-1 and PI3K signaling (Pirollo et al., 1997; Grana et al., 2002; Gupta et al., 2002) . These data underscore the importance of RAF-1 functions in mitogenic and cell survival signaling pathways and validate RAF-1 as a molecular target for cancer drug discovery.
Evolution of the antisense RAF-1 therapeutic strategy
Antisense therapeutics is an attractive target-specific concept for cancer drug development (Crooke, 1992; Agrawal, 1996; Koller et al., 2000; Stein, 2001 ). Inhibition of specific gene expressions can be accomplished by delivery of an antisense cDNA or antisense oligodeoxyribonucleotide sequence (AON) complementary to a selected gene-specific sequence. We and others have demonstrated that human tumor cells transfected with antisense c-RAF-1 cDNA, but not sense c-RAF-1 cDNA, show inhibition of RAF-1 expression, delayed tumor growth, and enhanced sensitivity to IR or the drug paclitaxel (Kasid et al., 1989; Rasouli-Nia et al., 1998) . Subsequently, antisense oligonucleotides (15 mer and 25 mer) were designed against the translation initiation site of c-RAF-1 mRNA (rafAON) (Kasid et al., 1991; Soldatenkov et al., 1997) . The rafAON sequences were designed such that either the terminal bases at the 5 0 -and 3 0 -ends were phosphorothioated (ends-modified-oligos) or all bases were phosphorothioated (PS-oligos). Expression and enzymatic activities of RAF-1 protein were shown to be inhibited in a sequence-specific manner in radioresistant head and neck squamous carcinoma cells (SQ-20B) treated with the rafAON compared with the sense oligo-treated counterparts and untreated cells. In vitro, clonogenic radiation survival dose response experiments demonstrated rafAON-associated radiosensitization of SQ-20B cells (Figure 1a ). The dose-modifying factor of the rafAON treatment was 1.4. These studies suggested rafAON as a DNA-sequence-specific radiosensitizer with potential use in conjunction with radiation therapy of cancers.
The potencies of AONs with the phosphodiester backbone or ends-modified AONs are limited by nuclease sensitivity (Agrawal, 1999) . For in vivo use, antisense oligonucleotides must be stabilized against rapid hydrolysis in plasma. Introduction of phosphorothioate (PS) linkages has been shown to confer nuclease resistance (Monia et al., 2000) . Preclinical development of a PS-antisense oligonucleotide complementary to the 3 0 -untranslated region of c-RAF-1 mRNA (ISIS 5132) was undertaken based on its potency to inhibit RAF kinase expression and tumor growth (Monia et al., 1996) . Mouse studies revealed hepatotoxicity at doses of 100 mg/kg, features of lymphohematopoietic cell proliferation at 20 mg/kg and no effects at 10 mg/kg. Monkey studies revealed transient prolongation of the aPTT and complement activation at 10 mg/ kg, but no effect on other hematologic or chemistry values nor histologic abnormality; the complement and coagulation effects were not observed at 3 mg/kg (Monteith et al., 1998) . For further information on the preclinical studies of ISIS 5132, the reader is refered to a previous publication (Monia et al., 2000) . Toxicity studies of PS-oligos have shown side effects in animals and humans, perhaps due to the polyanionic nature of PS-oligos (Agrawal, 1999) . Another attractive method for stabilizing systemically administered AON is encapsulation in liposomes. Liposomal encapsulation of AON may provide more sustained levels of oligonucleotides, with higher concentrations delivered to cells, and allow delivery of AON without requiring phosphothioate modification of all residues. Several lipid formulations have been used for intracellular delivery of nuclease-resistant oligonucleotides (Tari et al., 1998; Garcia-Chaumont et al., 2000; Pagnan et al., 2000; Leonetti et al., 2001) . We have designed novel cationic liposomes for in vivo delivery of nuclease-sensitive or phosphorothioated oligonucleotides (Gokhale et al., 1997 (Gokhale et al., , 1999 . The nuclease-sensitive RAF antisense oligonucleotide (rafAON) (15 mer) was complementary to the translation initiation region of c-RAF-1 mRNA. The phosphorothioate modification in rafAON is limited to the terminal bases at the 5 0 -and 3 0 -ends . Using fluorescence-labeled rafAON, we have demonstrated that rafAON is entrapped in the lipid bilayer of the liposome, facilitating endocytosis via association of the cationic lipids with negatively charged plasma membrane. Pharmacokinetic and tissue distribution studies have indicated that while free rafAON undergoes degradation within minutes of intravenous administration in athymic mice, liposome-encapsulated rafAON is stable in plasma and tissues for up to at least 24 h. Moreover, liposome-encapsulated rafAON inhibits RAF-1 expression and enhances the radiation sensitivity of radioresistant head and neck squamous carcinoma cells.
The cationic liposomal formulation also results in improved pharmacokinetics and antitumor efficacy of PS-antisense RAF oligonucleotide (ISIS 5132/5132). We compared the pharmacokinetic parameters of liposomeencapsulated 5132 (LE-5132) and 'free' 5132. The peak plasma concentrations at 5 min following PS-AON administrations (30 mg/kg, i.v.) were 28.5 and 13.5 g/ ml for LE-5132 and 5132, respectively. The area under the plasma concentration curve (AUC) was 5.8 times higher with LE-5132 as compared with 5132. Significantly higher, intact AON levels could be measured in most organs within 48 h of administration of LE-5132 compared with 5132. LE-5132 composition, unlike 5132, did not affect clotting time in vitro. A significant decline in the level of RAF-1 protein was observed in vitro in the radioresistant human laryngeal squamous cell carcinoma cells (SQ-20B) treated with LE-5132 compared with SQ-20B cells treated with equimolar concentrations of 5132 or liposome-encapsulated mismatched 5132. In addition, LE-5132 appeared to be a more potent antitumor compound than 5132 (Po0.001). Intravenous administration of LE-5132 into SQ-20B tumorbearing athymic mice inhibited RAF-1 expression in tumor tissue compared with blank liposome-treated or untreated control groups. LE-5132 or IR treatment alone caused significant but transient inhibition of SQ-20B tumor growth, but not tumor regression. Remarkably, a combination of LE-5132 and IR treatments led to significant and sustained tumor regression for at least 27 days after the last treatment (Po0.001) (Figure 1b) . Histopathological examination of tumor samples revealed a significant proportion of cells containing fragmented chromatin in the LE-5132 þ IR treatment group as compared with single agent and untreated control groups.
The liposomal formulation has been used to evaluate the preclinical performance of nuclease-sensitive, endsmodified rafAON in animal model systems . Toxicity of the liposome-entrapped rafAON (LErafAON) was investigated in CD2F1 mice given 12 i.v. doses at four dose levels: 5, 15, 25 and 35 mg/kg/dose; control groups were treated with equal quantities of blank liposomes (BL) or left untreated. No clinical toxicity or death was observed in any group. A dose-dependent increase in neutrophil count and elevations of liver enzymes AST and ALT were recorded. Mild-to-moderate dose-related diffuse hepatitis was observed in treated mice, with minimal hepatocellular necrosis. These findings were more pronounced at higher doses of LErafAON than in corresponding BLtreated control mice. Toxicity of LErafAON was assessed in NZW rabbits at a dose of 6.5 mg/kg/dose given intravenously Â six doses or 3.75 mg/kg/dose i.v. Â eight doses. No drug-related toxicities were detected clinically by hematologic or chemistry evaluations, coagulation profiles, serum complement determinations, or by gross and microscopic pathology as compared with BL-or normal saline-treated control groups.
Toxicity of LErafAON was also investigated in cynomolgus monkeys using slow intravenous injection Â nine doses (3.75 or 6.25 mg/kg/dose). A mild monocyte increase and the presence of vacuolated macrophages were noted in the spleens, livers and kidneys of all treatment groups. This has been attributed to administration of liposomes per se. Coagulation profiles of LErafAON and BL groups were comparable to their respective baseline values. Interestingly, complement activation was documented in all treatment groups. Unlike PS-oligos where complement activity has been related to plasma concentrations of the oligonucleotide (Henry et al., 1997) , rafAON per se does not appear to contribute to changes in complement activity observed in monkeys. These changes are likely to be attributed to liposomes rather than rafAON. Relative RAF-1 protein levels in liver specimens 24 h after the last dose of LErafAON were 60.9714.1% (males) and 56.6726.6% (females) compared with the BL-treated group (n ¼ 3). These data suggest that inhibition of RAF-1 per se is not correlated with the observed mild liver toxicity in BL-and LErafAON-treated animals. Additional studies revealed a favorable pharmacokinetics and normal tissue distribution profiles of intact rafAON in athymic mice and monkeys following LErafAON administration. In athymic mice bearing human prostate tumor xenografts (PC-3), significant levels of intact rafAON were also detected in PC-3 tumor tissue for up to 48 h, suggesting that these liposomes are a suitable vehicle for delivery of nuclease-sensitive, ends-modified rafAON to tumor tissue.
Antitumor efficacy studies in PC-3 tumor-bearing Balb/c nu/nu mice showed that LErafAON alone (25 mg/kg/dose, i.v., 10 Â ) caused prostate tumor growth arrest compared with control groups of mice (untreated and BL) for up to 12 days after the last dose. This was followed by a steady increase in the mean percentage (%) tumor volumes. Similar observations were made in the IR alone group (3.8 Gy/day, 5 Â ). The combination of LErafAON and IR treatments caused a significant and steady decline in the mean % tumor volumes (Day 46, the mean % tumor volumes compared with initial (pretreatment) tumor volumes (Day 0): untreated, UT, 870.07192.0%; blank liposomes, BL, 963.07397.0%; liposome-entrapped mismatch AON, LEMMAON, 803.07325%; LErafAON, 230.0755.0%; IR, 220.0744.0%; LErafAON þ IR, 21.077.0%). Single treatment groups (LErafAON and IR) displayed significant tumor growth arrest as compared with the untreated control group (Po0.001). Most importantly, the LErafAON þ IR combination group displayed significantly greater antitumor activity as compared to either treatment alone or to the control groups (Figure 1c ; Day 46, Po0.001).
Inhibition of RAF-1 expression was noted in PC-3 tumor tissues in mice treated with LErafAON or with a combination of LErafAON and IR (approximately 65% of the untreated group). Inhibition of RAF-1 expression was also noted in all normal tissues examined from mice treated with LErafAON as compared with control groups (BL/UT). These data demonstrate that a combination of LErafAON and IR treatments is effective in a hormone refractory prostate tumor model system.
Clinical translation: phase I radiation therapy and LErafAON
Clinical investigations of antisense oligonucleotides targeting RAF-1 have included Phase I trials of ISIS 5132 (Monia et al., 2000) and Phase I trials of LErafAON as a single agent and in conjunction with IR Rudin et al., 2002) . A total of 31 patients received a 2-hour infusion of ISIS 5132 three times weekly for 9 weeks. The maximum dose was established at 6.0 mg/kg/dose. Prolongation of the prothrombin time and dose-related transient complement activation have been observed with this drug (Holmlund et al., 1998; O'Dwyer et al., 1999; Stevenson et al., 1999; Cunningham et al., 2000; Rudin et al., 2001a, b) .
A Phase I clinical trial of LErafAON (Neopharm, Inc.) tested weekly infusion of the drug for 8 weeks as a single agent treatment in patients with various advanced, chemotherapy refractory tumors. In all, 22 patients were entered, and the maximum dose of 6.0 mg/ kg/week was established. Observed patient toxicity was associated with liposome sensitivity reactions, which were managed with pretreatment use of steroids and antihistamines. A second Phase I clinical trial was performed using daily infusions of LErafAON over 2 weeks in combination with daily radiation treatments (3000 cGy in 10 fractions). The final cohort was performed using twice-weekly infusions of 2.0 mg/kg/ day. Liposomal sensitivity reactions were observed, and there were no unanticipated radiation reactions.
These clinical data have demonstrated acceptable patient tolerance of two preparations of antisense RAF oligonucleotides, targeting either the translation initiation region (LErafAON) or the 3 0 -untranslated region of c-RAF-1 mRNA (ISIS 5132). Studies using the liposomal preparation (LErafAON) have demonstrated intact rafAON in plasma and in normal and tumor tissues. Furthermore, combining LErafAON with radiation therapy has been shown to be efficacious treatment. Since preclinical observations demonstrate that RAF inhibition is cytostatic unless combined with radiation therapy or chemotherapy (unpublished data), such combinations warrant further investigations.
RAF-1 pathway and future prospects of radiosensitization
The RAF-1 protein plays an important role in radiation survival responses, in vitro and in vivo. RAF-1 also regulates cell growth and proliferation, differentiation and angiogenesis. A cell type-specific crosstalk between the components of these pathways and the mechanisms of cell survival offers the potential for differential tumor effects. Radiation is expected to introduce additional levels of regulation of various molecules within the RAF-1 signaling pathway. These include EGFR Reardon et al., 1999) , bFGF (HaimovitzFriedman et al., 1991 (HaimovitzFriedman et al., , 1994 , transforming growth factor-a (TGF-a) , VEGF (Gorski et al., 1999) , Grb2-SOS (Suy et al., 1997) , RAS (Suy et al., 1997) , PKC , RAF-1 (Kasid et al., 1996; Suy et al., 1997) and ERK (Kharbanda et al., 1994; Kasid et al., 1996; Suy et al., 1997; Dent et al., 1999) .
Pharmacological agents designed to block specific targets along this pathway(s) have been used to demonstrate enhanced cytotoxic/antitumor effects in combination with ionizing radiation in several cell model systems (Figure 2 ). These agents include the monoclonal antibody C225 (Huang et al., 1999; Milas et al., 2000) , dominant negative inhibitor EGFR-CD533 Lammering et al., 2001 ) and the small-molecule inhibitor ZD1839 (Bianco et al., 2002) targeting the EGFR; and the monoclonal antibody DC101 (Kozin et al., 2001 ) and small-molecule inhibitor SU5416 (Geng et al., 2001) targeting the VEGF receptor (VEGFR). PKC inhibition via smallmolecule inhibitor PKC412 causes radiosensitization (Tenzer et al., 2001) . Blockade of RAS activity via inhibition of farnesyltransferase and radiosensitization has been demonstrated using small-molecule inhibitor L744,832 (Gupta et al., 2002) . Several studies have reported radiosensitization following inhibition of PI3K using small-molecule inhibitor LY294002 (Rosenzweig et al., 1997; Gupta et al., 2001 Gupta et al., , 2002 Grana et al., 2002) or via the tumor suppressor PTEN (Wick et al., 1999) .
As discussed earlier, in vitro and in vivo radiosensitization has been demonstrated via sequencespecific inhibition of RAF-1 using antisense oligonucleotide, AS RAF ODN ; liposome-entrapped, phosphorothioated AON, LE5132 (Gokhale et al., 1999) ; and liposome-entrapped, endsmodified AON, LErafAON . Inhibition of MEK, a downstream effector of RAF-1, via a small-molecule inhibitor PD98059 also enhances cytotoxicity when combined with radiation (Carter et al., 1998; Dent et al., 1999) .
Additional agents capable of directly or indirectly modulating the RAF-1 pathway may be the monoclonal antibody LM609 (Gutheil et al., 2000) , small-molecule inhibitors UCN-01 (Dai et al., 2001) , BAY 43-9006 (Awada et al., 2001; Strumberg et al., 2001) and CI-1040 (Sebolt-Leopold et al., 1999 , or antisense oligonucleotides ISIS3521 (Nemunaitis et al., 1999) , ISIS5132 (Monia et al., 2000; Rudin et al., 2001a, b) and G3139 (Waters et al., 2000; Rudin et al., 2001a, b) (Figure 2 ). More recently, a mutant RAF-1 (ATP m -Raf) has been shown to cause tumor regression of primary and metastatic tumors (Hood et al., 2002) . In addition, inhibitor protein RKIP appears to be a candidate therapeutic molecule capable of targeting two established pathways downstream of RAF-1, the ERK and NF-kB signaling (Kolch et al., 2000; Yeung et al., 2001) .
Inhibition of RAF-1 expression via RAF antisense oligonucleotide appears to be associated with modulation of the steady-state mRNA levels of several known and novel genes in human cancer cells (unpublished studies). Interestingly, irradiation of normal and tumor cells also causes modulation of gene expression (Khodarev et al., 2001) . It is likely that downstream effectors, yet to be identified, play roles in the enhanced antitumor effects seen with a combination of LErafAON and radiation. Future studies should delineate mechanisms underlying the radiobiological specificity of the RAF-1 signaling pathway. This may include investigations of pro/antiapoptotic molecules, cytoskeletal proteins, cell cycle regulatory proteins, oncogenic/tumor suppressor proteins, or metastatic/angiogenic molecules. Knowledge of the effectors of RAF-1, displaying a role in the radiation response of cells, should foster new paradigms, facilitating a multitargeted, tailored radiosensitization approach for the treatment of radioresistant cancers. 
